Antibody-mediated suppression of Vβ5.2/5.3 + T cells in multiple sclerosis: Results from an MRI-monitored phase II clinical trial

Annals of Neurology

Volumn 51, Issue 4, 2002, Pages 467-474

  Killestein, Joep ^a   Olsson, Tomas ^b   Wallström, Erik ^a   Svenningsson, Anders ^a   Khademi, Mohsen ^f   Blumhardt, Lance D ^e   Fagius, Jan ^d   Hillert, Jan ^b   Landtblom, Anne Marie ^c   Edenius, Charlotte ^e   Årfors, Leopold ^d   Barkhof, Frederik ^a   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e ASTRAZENECA   (United Kingdom)

^f QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ATM 027; GADOLINIUM PENTETATE; GAMMA INTERFERON; HLA DR2 ANTIGEN; IMMUNOGLOBULIN G1; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; MYELIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; BRAIN INJURY; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RELAPSE; REMISSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AMINO ACID SEQUENCE; AUTOANTIGENS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HAPLOTYPES; HLA-DR2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0036195802     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10146     Document Type: Article

References (31)

1. Immunopathogenesis of multiple sclerosis: The role of T cells
2. Major T cell responses in multiple sclerosis
3. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis
4. Autoreactive T lymphocytes in multiple sclerosis determined by antigen- induced secretion of interferon-gamma
5. Immunological aspects of demyelinating diseases
6. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis
7. + T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients
8. Biased usage of TCR V beta 5.2/5.3 by T cells in the CSF and among PBMC with spontaneous and MBP 80-102 induced IFN gamma expression in MS patients
9. T cell receptor V beta 5 and V beta 17 clonal diversity in cerebrospinal fluid and peripheral blood lymphocytes of multiple sclerosis patients
10. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis
11. Selective in vivo depletion of TCR V beta 5.2/5.3 expressing T cells in patients with multiple sclerosis
12. Selective in vivo depletion of TCR V beta 5.2/5.3 T cells in MS patients reduces IFN gamma mRNA expression and MBP 80-102 reactive T cells (abstract)
13. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
14. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
15. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
16. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis
17. Detection of intracellular expression and secretion of interferon-gamma at the single-cell level after activation of human T cells with tetanus toxoid in vitro
18. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis
19. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
20. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
21. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial
22. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans
23. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
24. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
25. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis
26. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
27. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial
28. T cell receptor V genes in multiple sclerosis: Increased use of TCRAV8 and TCRBV5 in MBP-specific clones
29. Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis
30. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis
31. Lack of restriction of T cell receptor beta variable gene usage in cerebrospinal fluid lymphocytes in acute optic neuritis